Wedbush Reiterates Outperform Rating on BridgeBio Oncology Therapeutics, In (BBOT)
Tweet
Share
E-mailGet Alerts BBOT Hot Sheet
Price: $9.20 -0.86%
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 23 | New: 12
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 23 | New: 12
Join SI Premium – FREE
Wedbush analyst David Nierengarten reiterated an Outperform rating and $25.00 price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT)
For an analyst ratings summary and ratings history on BridgeBio Oncology Therapeutics, In click here. For more ratings news on BridgeBio Oncology Therapeutics, In click here.
Shares of BridgeBio Oncology Therapeutics, In closed at $ yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BridgeBio Oncology Therapeutics, Inc. (BBOT) Misses Q2 EPS by 70468c
- Vogenx prices IPO at $13 per share, raising $81.3M
- JPMorgan Upgrades Multi Commodity Exchange of India Ltd (MCX:IN) to Overweight
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
